ANALGESICS IN GREECE

Euromonitor International

February 2019

LIST OF CONTENTS AND TABLES

Headlines

Prospects

Growth Hindered by the Prevalence of Non-otc Brands

Specialised Products Could Give A Boost in Value

Demand for Quick Relief Drives Growth for Max Strength Products

Competitive Landscape

Depon Leads Analgesics Sales

Gsk Consumer Healthcare Gains Share, Driven by Panadol's Good Performance

Bayer Expands Its Aspirin Portfolio

Category Data

Table 1 Sales of Analgesics by Category: Value 2013-2018

Table 2 Sales of Analgesics by Category: % Value Growth 2013-2018

Table 3 Sales of Topical Analgesics/Anaesthetic by Format: % Value 2013-2018

Table 4 NBO Company Shares of Analgesics: % Value 2014-2018

Table 5 LBN Brand Shares of Analgesics: % Value 2015-2018

Table 6 Forecast Sales of Analgesics by Category: Value 2018-2023

Table 7 Forecast Sales of Analgesics by Category: % Value Growth 2018-2023

Executive Summary

Consumer Health Reshaped by Legislative Changes

Sales Increase Amid Price Hikes and An Increase in Self-medication

Depon Remains the Undisputed Leading Brand

Despite the Liberation of OTC Products' Distribution, Chemists/pharmacies Continues To Hold the Lion's Share

Forecasts Are Optimistic for Consumer Health

Market Indicators

Table 8 Consumer Expenditure on Health Goods and Medical Services: Value 2013-2018

Table 9 Life Expectancy at Birth 2013-2018

Market Data

Table 10 Sales of Consumer Health by Category: Value 2013-2018

Table 11 Sales of Consumer Health by Category: % Value Growth 2013-2018

Table 12 NBO Company Shares of Consumer Health: % Value 2014-2018

Table 13 LBN Brand Shares of Consumer Health: % Value 2015-2018

Table 14 Distribution of Consumer Health by Format: % Value 2013-2018

Table 15 Distribution of Consumer Health by Format and Category: % Value 2018

Table 16 Forecast Sales of Consumer Health by Category: Value 2018-2023

Table 17 Forecast Sales of Consumer Health by Category: % Value Growth 2018-2023

Appendix

OTC Registration and Classification

Vitamins and Dietary Supplements Registration and Classification

Self-medication/self-care and Preventive Medicine

Switches

Sources

Summary 1 Research Sources

Analgesics is the second largest category within OTC in Greece in value terms. The low retail price of Depon, together with the wide use of brands that do not have an OTC status for pain relief, such as Mesulid or Ponstan, are the main factors behind the low per capita spending on OTC analgesics in Greece.

Euromonitor International's Analgesics in Greece report offers a comprehensive guide to the size and shape of the market at a national level. It provides the latest retail sales data 2014-2018, allowing you to identify the sectors driving growth. Forecasts to 2023 illustrate how the market is set to change.

Product coverage: Systemic Analgesics, Topical Analgesics/Anaesthetic.

Data coverage: market sizes (historic and forecasts), company shares, brand shares and distribution data.

Why buy this report?
* Get a detailed picture of the Analgesics market;
* Pinpoint growth sectors and identify factors driving change;
* Understand the competitive environment, the market’s major players and leading brands;
* Use five-year forecasts to assess how the market is predicted to develop.

Euromonitor International has over 40 years' experience of publishing market research reports, business reference books and online information systems. With offices in London, Chicago, Singapore, Shanghai, Vilnius, Dubai, Cape Town, Santiago, Sydney, Tokyo and Bangalore and a network of over 800 analysts worldwide, Euromonitor International has a unique capability to develop reliable information resources to help drive informed strategic planning.